Arcellx Inc. Common Stock

Arcellx Inc. a clinical-stage biotechnology company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001 an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics Inc. and changed its name to Arcellx Inc. in January 2016. Arcellx Inc. was incorporated in 2014 and is headquartered in Gaithersburg Maryland.